Physician profile
David T Chen
NPI 1891719852
$5,711.43
in general payments reported to CMS, 2019-2025
21 companies · $831 in 2025
The $831 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $513 · 2021: $720 · 2022: $888 · 2023: $1,303 · 2024: $570 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,407.82 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $747.30 | 2019-2025 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $679.83 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Astrazeneca Pharmaceuticals LP | $550.34 | 2019-2025 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.40 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $361.44 | 2020-2021 | |
| Philips North America LLC | $326.58 | 2019-2020 | |
| Novo Nordisk INC | $202.73 | 2021-2023 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $197.62 | 2021-2023 | |
| Lilly USA, LLC | $191.96 | 2021-2023 | Mounjaro |
| Stryker Corporation | $155.56 | 2025 | Stryker |
| Merck Sharp & Dohme LLC | $131.36 | 2019-2022 | |
| Pfizer INC. | $130.57 | 2023-2025 | |
| Abbvie INC. | $92.33 | 2023 | Linzess, Viberzi, Creon |
| Agios Pharmaceuticals, INC. | $34.31 | 2025 | Pyrukynd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.38 | 2019 | |
| Medline Industries LP | $19.79 | 2023 | Z-Guard |
| Phadia US INC. | $15.70 | 2023 | Immunocap |
| Arbor Pharmaceuticals, INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.